ProSciento, Inc.

At ProSciento, our Clinical Team Managers (CTMs) are at the heart of our clinical study operations. With an impressive average of 8 years prior CTM experience, 97% retention rate, and a focus on only 1-2 studies at a time, our CTMs provide each sponsor with the expertise and attention they deserve. Our CTMs are operational experts, ensuring: • A culture of cross-functional collaboration with PMs, DMs, CRAs, and sites, with an unwavering focus on quality, timelines and exceeding sponsor expectations • Relationship-driven site management that enables reliably faster study start-up • Proactive study orchestration: Managing timelines, metrics, and ensuring all documentation is inspection-ready • Active issue resolution, minimizing data backlog, and maintaining reliably high SDV rates (>85% SDV completion) We're immensely proud of the commitment and passion our CTMs bring to each study. Their commitment goes far beyond "checking boxes" – they work tirelessly to make others' jobs easier and to keep every aspect of the study moving forward efficiently. Discover how our specialized team delivers unmatched value and efficiency in metabolic clinical trials: https://bit.ly/41ID4uP #MetabolicContinuum #ScienceDriven #PatientFocused #MetabolicCRO

We're proud to announce that ProSciento will once again sponsor and attend the Breakthrough T1D Walk in San Diego on Sunday, November 2, 2025, at NTC Park in Liberty Station.   As a longtime supporter of this event, we're honored to join thousands of others in raising awareness, celebrating the T1D community, and supporting Breakthrough T1D's mission to accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes.   If you'll be at the Walk, stop by the ProSciento tent to connect with our team and pick up some event-day swag. We look forward to walking together in support of the T1D community!   Event Details: Location: NTC Park, Liberty Station (San Diego) Time: 8:30 AM Don't forget to stop by our ProSciento tent!   #BreakthroughT1D #ProSciento #MetabolicCRO

At ProSciento, we believe the future of clinical trial recruitment lies in direct, trusted relationships with patients and sites, not transactional outreach. Our Patient & Site Services (PSS) model was designed to transform enrollment by connecting sponsors with individuals who have actively chosen to engage in research, rather than relying on outdated or passive databases. These relationships drive higher enrollment rates, strengthen retention, and ensure that trial design remains patient-centered. Key aspects of our approach include: • Direct-to-Patient Engagement: Participants are stakeholders whose voices help shape study design. • Precision Recruitment: Data-driven profiling and prescreening tools align the right patients with the right trials. • Site Partnership: Dedicated coordinators and real-time performance insights reduce barriers and support site success. • Comprehensive Support: Concierge services, such as travel assistance and reminders, help ensure a seamless experience for participants from first contact through study completion. With more than two decades of experience in metabolic disease research, ProSciento’s integrated platform is redefining how sponsors, sites, and patients collaborate. The result is smarter recruitment, faster enrollment, and stronger retention. Read more about the differentiators of our Patient & Site Services: https://bit.ly/46iD2eR #MetabolicContinuum #ScienceDriven #PatientFocused #MetabolicCRO

ProSciento’s services are grounded in science and powered by decades of industry knowledge. From trial design to execution and regulatory submissions, our integrated approach ensures high-performing sites, eligible patient enrollment, and operational excellence. This scientific foundation supports sponsors, sites, and patients throughout every step of the clinical study program. ProSciento is not just a CRO, but a recognized thought leader in metabolic research. Our commitment to advancing the scientific field is demonstrated by: › 330+ peer-reviewed publications › 200+ early clinical development protocols developed for biologics, small molecules, and devices › Two textbooks authored on translational research methods in metabolic R&D › Active participation of ProSciento scientists on editorial boards and conference panels These contributions underscore our mission to not only execute clinical trials with excellence but also shape the future of metabolic medicine through scientific leadership and transparency. Connect with a ProSciento team member: https://bit.ly/41ID4uP #MetabolicContinuum #ScienceDriven #PatientFocused #MetabolicCRO

We're headed to sunny Scottsdale for the 2025 American Thyroid Association, Inc. (ATA) Annual Meeting, the world's largest gathering of thyroid specialists!   ProSciento's Chief Operating Officer, Megan McCormick, and Executive Director of Patient & Site Services, Maria Nunez, will be on site connecting with leaders in clinical research and endocrine care to exchange insights on advancing thyroid disease innovation.   As a specialty CRO focused exclusively on diseases across the metabolic continuum, including thyroid disorders, we're proud to contribute to conversations that shape early-phase trial design, patient engagement, and study execution in this critical therapeutic area.   Scottsdale, AZ | Sept 10–14, 2025   Interested in scheduling a meeting while on-site? Reach out directly to Megan.McCormick@prosciento.com or Maria.Nunez@prosciento.com to connect.   #ATA2025 #ThyroidResearch #Endocrinology #MetabolicContinuum #ScienceDriven #PatientFocused #ClinicalTrials

Planning your European Association for the Study of Diabetes e.V. (EASD) 2025 schedule? Let's connect. Marcus Hompesch, Alejandra Macias Pulido, MD, and Casey Ustick from the ProSciento team will be attending and are available for meetings throughout the conference. If you're looking to discuss science-driven strategies in clinical research for #Diabetes, #Obesity, or #SteatoticLiverDisease, we welcome the opportunity to connect. Schedule a meeting: https://lnkd.in/g3JSEv3H   #EASD2025 #ClinicalResearch #MetabolicContinuum #ScienceDriven

We're headed to the European Association for the Study of Diabetes e.V. (EASD) 2025!   ProSciento's Marcus Hompesch, Casey Ustick, and Alejandra Macias Pulido, MD will be attending and are available for meetings throughout the conference.   If you're interested in connecting to discuss science-driven clinical development strategies in #Diabetes, #Obesity, and #SteatoticLiverDisease, we'd love to meet. Schedule your meeting today: https://lnkd.in/g3JSEv3H   #EASD2025 #ClinicalResearch #MetabolicContinuum #ScienceDriven

ProSciento's Patient & Site Services (PSS) strategy proves that clinical trial enrollment success isn't about the biggest database; it's about the most relevant data. We built our proprietary database of 180,000+ individuals on quality and engagement, not volume alone. Every participant has expressed interest in clinical research, and ongoing outreach ensures the list stays current with actively engaged individuals. With participant consent, our team conducts 1,700+ prescreens each month to assess eligibility and protocol-specific interest. This precision-driven approach delivers highly qualified referrals to sites, enabling faster enrollment, reduced screen failures, and stronger retention. Key outcomes: • 25% lower screen failure rates through rigorous prescreening • 90% on-time enrollment by aligning feasibility with engaged participants • 92% retention by matching the right participants to the right sites Connect with a ProSciento Patient & Site Services expert: https://bit.ly/41ID4uP #MetabolicContinuum #ScienceDriven #PatientFocused #MetabolicCRO

At ProSciento, we don't ask sponsors to fit into a rigid set of CRO services; we build a partnership model that adapts to the unique needs of each study. Sponsors have access to our full scope of CRO capabilities, with services tailored to each protocol and direct collaboration with senior leadership and scientific advisors for rapid, informed decision-making. Our track record: • 20+ years of exclusive focus on metabolic disease clinical research • 450+ clinical trials completed for sponsors of all sizes • 200+ early clinical development protocols for biologics, small molecules, and devices • Contributions to 20 metabolic drugs and devices now on the market Connect with our business development team to design a tailored service plan for your next clinical study: https://bit.ly/41ID4uP #MetabolicContinuum #ScienceDriven #PatientFocused #MetabolicCRO